TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells.

作者: Jie Hui Li , Nancy C. Kirkiles-Smith , Jennifer M. McNiff , Jordan S. Pober

DOI: 10.4049/JIMMUNOL.171.3.1526

关键词:

摘要: Human TRAIL can efficiently kill tumor cells in vitro and human xenografts mice with little effect on normal mouse or tissues. The effects of tissues have not been described. In this study, we report that endothelial (EC), isolated from umbilical veins dermal microvessels, express death domain-containing TRAIL-R1 -R2. Incubation for 15 h causes approximately 30% cultured EC to die, as assessed by propidium iodide uptake. Death is apoptotic, Annexin V staining, 4',6'-diamidino-2-phenylindole DNA fragment ELISA. increased cotreatment cycloheximide but significantly reduced caspase inhibitors transduced dominant-negative Fas-associated domain protein. surviving cells, activates NF-kappaB, induces expression E-selectin, ICAM-1, IL-8, promotes adhesion leukocytes. Injection into skin focal injury accompanied limited neutrophil infiltration. These data suggest an inducer tissue humans, outcome may influence antitumor therapy TRAIL.

参考文章(39)
Bart Everaerdt, Claude Libert, Walter Fiers, Peter Brouckaert, Selective species specificity of tumor necrosis factor for toxicity in the mouse. Lymphokine and cytokine research. ,vol. 11, pp. 193- 196 ,(1992)
Henning Walczak, Robert E. Miller, Kiley Ariail, Brian Gliniak, Thomas S. Griffith, Marek Kubin, Wilson Chin, Jon Jones, Anne Woodward, Tiep Le, Craig Smith, Pam Smolak, Raymond G. Goodwin, Charles T. Rauch, JoAnn C.L. Schuh, David H. Lynch, Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nature Medicine. ,vol. 5, pp. 157- 163 ,(1999) , 10.1038/5517
B B Aggarwal, M A Palladino, S M Kramer, M R Shalaby, A B Deleo, R A Baughman, D Crase, B Marafino, B L Ferraiolo, I S Figari, Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. Journal of Immunology. ,vol. 138, pp. 4023- 4032 ,(1987)
Michael A. Palladino, John S. Patton, Irene S. Figari, M. Refaat Shalaby, Possible relationships between in vivo antitumour activity and toxicity of tumour necrosis factor-alpha. Ciba Foundation symposium. ,vol. 131, pp. 21- 38 ,(1987) , 10.1002/9780470513521.CH3
Giorgio Zauli, Paola Secchiero, Alessandra Bassini, Lia Guidotti, Sabina Pierpaoli, Marco Vitale, Emad S. Alnemri, Stefano Papa, Loris Zamai, TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis Blood. ,vol. 95, pp. 3716- 3724 ,(2000) , 10.1182/BLOOD.V95.12.3716
Drew M. Pardoll, Spinning molecular immunology into successful immunotherapy Nature Reviews Immunology. ,vol. 2, pp. 227- 238 ,(2002) , 10.1038/NRI774
Minji Jo, Tae-Hyoung Kim, Dai-Wu Seol, James E. Esplen, Kenneth Dorko, Timothy R. Billiar, Stephen C. Strom, Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand Nature Medicine. ,vol. 6, pp. 564- 567 ,(2000) , 10.1038/75045
Jordan S. Pober, Barbara C. Biedermann, Human vascular endothelial cells favor clonal expansion of unusual alloreactive CTL. Journal of Immunology. ,vol. 162, pp. 7022- 7030 ,(1999)
Jordan U. Gutterman, Jaffer A. Ajani, Bernard Levin, Samuel Saks, James L. Abbruzzese, Karen Ende, Yehuda Z. Patt, Jack S. Faintuch, Charlene Edwards, Phase I trial of recombinant human γ-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer Cancer Research. ,vol. 49, pp. 4057- 4061 ,(1989)
Henning Walczak, Peter H. Krammer, The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Experimental Cell Research. ,vol. 256, pp. 58- 66 ,(2000) , 10.1006/EXCR.2000.4840